TORONTO, Feb. 28, 2017 /CNW/ - Merus Labs International
Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is
responding to a higher than average trading volume in the Company's
shares today. Merus is aware of a news story from Reuters
suggesting that it has hired Rothschild & Co. to explore
strategic alternatives.
The Company is currently using Rothschild to provide investment
banking and financial advisory services. Rothschild is
supporting Merus in its evaluation of a broad range of options
related to capital structure, product acquisitions, and corporate
transactions, which could include a sale or merger of the
Company.
Investors are cautioned that the engagement of a financial
advisor should not be viewed as an indication that any specific
process or transaction will be pursued. Merus does not intend
to comment further except as required by applicable securities laws
or the policies of the Toronto Stock Exchange.
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on
acquiring and optimizing established and growth products. The
Company leverages its expertise and commercial platform in
Europe, Canada and select other markets to deliver
value.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities legislation. Forward-looking
statements include statements relating to the Company's future
business and operating plans, including potential changes to
capital structure, product acquisitions or prospective corporate
transactions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from any future
results expressed or implied by these statements. Such factors
include the following: general economic and business conditions,
changes in demand for Merus' products, changes in competition,
the ability of Merus to integrate acquisitions or
complete future acquisitions, Merus' ability to complete any
financing, interest rate fluctuations, currency exchange rate
fluctuations, dependence upon and availability of qualified
personnel and changes in government regulation. Investors should
refer to the Company's MD&A, Annual Information Form and Annual
Report on 40-F for the year ended September
30, 2016 for a more comprehensive discussion of the risks
that are material to the Company and its business. These
forward-looking statements speak only as of the date of this press
release, and Merus undertakes no obligation to update or revise the
statements.
SOURCE Merus Labs International Inc.